Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) (165)
Gynecologic Oncology(2022)
关键词
homologous recombination deficiency,serous ovarian cancer,heterozygosity,chemotherapy
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要